Your browser doesn't support javascript.
loading
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.
Wang, Lawrence T; Pereira, Lais S; Flores-Garcia, Yevel; O'Connor, James; Flynn, Barbara J; Schön, Arne; Hurlburt, Nicholas K; Dillon, Marlon; Yang, Annie S P; Fabra-García, Amanda; Idris, Azza H; Mayer, Bryan T; Gerber, Monica W; Gottardo, Raphael; Mason, Rosemarie D; Cavett, Nicole; Ballard, Reid B; Kisalu, Neville K; Molina-Cruz, Alvaro; Nelson, Jorgen; Vistein, Rachel; Barillas-Mury, Carolina; Amino, Rogerio; Baker, David; King, Neil P; Sauerwein, Robert W; Pancera, Marie; Cockburn, Ian A; Zavala, Fidel; Francica, Joseph R; Seder, Robert A.
Afiliação
  • Wang LT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pereira LS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Flores-Garcia Y; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • O'Connor J; Department of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia; The Australian National University Medical School, Canberra, ACT 2601, Australia.
  • Flynn BJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Schön A; Department of Biology, Johns Hopkins University, Baltimore, MD 21205, USA.
  • Hurlburt NK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Dillon M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Yang ASP; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Fabra-García A; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Idris AH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mayer BT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Gerber MW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Gottardo R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Mason RD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Cavett N; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ballard RB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kisalu NK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Molina-Cruz A; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
  • Nelson J; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Vistein R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Barillas-Mury C; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
  • Amino R; Unit of Malaria Infection and Immunity, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France.
  • Baker D; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • King NP; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Sauerwein RW; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Pancera M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Cockburn IA; Department of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.
  • Zavala F; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • Francica JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: rseder@mail.nih.gov.
Immunity ; 53(4): 733-744.e8, 2020 10 13.
Article em En | MEDLINE | ID: mdl-32946741
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their mechanisms of neutralization will facilitate translation for passive prophylaxis and aid next-generation vaccine development. Here, we isolated a neutralizing human mAb, L9 that preferentially bound NVDP minor repeats of PfCSP with high affinity while cross-reacting with NANP major repeats. L9 was more potent than six published neutralizing human PfCSP mAbs at mediating protection against mosquito bite challenge in mice. Isothermal titration calorimetry and multiphoton microscopy showed that L9 and the other most protective mAbs bound PfCSP with two binding events and mediated protection by killing SPZ in the liver and by preventing their egress from sinusoids and traversal of hepatocytes. This study defines the subdominant PfCSP minor repeats as neutralizing epitopes, identifies an in vitro biophysical correlate of SPZ neutralization, and demonstrates that the liver is an important site for antibodies to prevent malaria.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Anticorpos Antiprotozoários / Proteínas de Protozoários / Esporozoítos / Anticorpos Neutralizantes / Anticorpos Monoclonais / Antimaláricos Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Anticorpos Antiprotozoários / Proteínas de Protozoários / Esporozoítos / Anticorpos Neutralizantes / Anticorpos Monoclonais / Antimaláricos Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos